Page 22 - Assay Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test HaluGen's DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is...

Derek Thomson, Chief Executive Officer at AnteoTech. AnteoTech’s AnteoBind™ Supports First-of-its-Kind COVID-19 Home Test     Feb 23 2021 Read 941 Times AnteoTech's long-term customer Ellume has secured a $231.8 million agreement with the U.S. Government to support accelerated manufacture of its COVID-19 home test. The test uses AnteoTech’s unique AnteoBind™ technology to support significantly improved sensitivity, and is the first rapid self-test for SARS-CoV-2 detection authorised by the United States Food and Drug Administration (FDA...

Share this article Share this article ResearchAndMarkets.com's offering. In light of the COVID-19 pandemic, it is extremely timely to present a report on the status quo in emerging infectious diseases. While the current pandemic is troublesome and has disrupted normal life, it will follow its course and then fade away. Where could the next pandemic or epidemic come from? There are a number of diseases currently tracking as moving from the developed world to the developing world? Now with a global focus on testing, this update on all of the other diseases that could spread widely seems relevan...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Allen Institute For Cell Science Announces Leadership Changes December 11, 2020 GMT SEATTLE, Wash., Dec. 11, 2020 /PRNewswire/ -- The Allen Institute for Cell Science, a division of the Allen Institute, announced today that Ruwanthi (Ru) Gunawardane, Ph.D., has been named Executive Director, effective January 9, 2021, providing executive direction and leadership. Susanne Rafelski, Ph.D., Deputy Director, will manage and lead the scientific research. Rick Horwitz, Ph.D., will assume the role of the Inst...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Biofidelity appoints Robert Osborne as Chief Operating Officer Biofidelity LimitedDecember 10, 2020 GMT CAMBRIDGE, United Kingdom, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Biofidelity Ltd, the cancer diagnostics company, today announces the further expansion of its leadership team with the appointment of Dr. Robert Osborne as Chief Operating Officer. In addition to responsibility for the overall operation of the business at a time of rapid growth, Dr. Osborne will lead product development and validation, o...